Thu. Feb 6th, 2025

Update: Merck’s Clesrovimab Reduced RSV Disease, Hospitalization In Infants

ByLisa Luckas

10/17/2024
baby with 8 months old cardPhoto by Juan Encalada
  • Merck’s investigational RSV antibody, Clesrovimab (MK-1654), significantly reduced RSV disease and hospitalization in preterm and full-term infants.

Thu Oct 17 23:01:14 -0000 2024 UTC– Merck & Co., Inc. released news about their Clesrovimab (MK-1654) monoclonal antibody reducing RSV disease and hospitalizations in infants,

Respiratory Syncytial Virus RSV

RSV is the leading cause of hospitalization for infants, and is a seasonal infection. Like the flu, it is a worldwide burden in infants and older adults. It may lead to respiratory conditions like bronchiolitis and pneumonia. It is estimated to cause 101,000 deaths a year worldwide in children under five.

RSV season usually starts in the fall and peaks in the winter in most regions of the United States and Europe.

Results from MK-1654-004 met all endpoints, with consistent results through both the 5-month and 6-month periods. The incidence of adverse events (AEs) and serious AEs were comparable between the clesrovimab and placebo groups, and there were no treatment or RSV-related deaths during the study, Merck & Co said.

Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:

About Lisa

Subscribe to Lisa’s Newsletter today!

Keep Up: Nobot.News Launches Breaking Newsletter

Read more Business News as it happens!

Business

ByLisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *